Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Ajay K. Nooka(Emory University), Amrita Krishnan(City of Hope), Jesús F. San Miguel(Clinica Universidad de Navarra), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Lionel Karlin(Hôpital Lyon Sud), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Ajai Chari(Icahn School of Medicine at Mount Sinai), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Albert Oriol Rocafiguera(Institut Català d'Oncologia), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Philippe Moreau(Centre National de la Recherche Scientifique), Alfred L. Garfall(University of Pennsylvania), Surbhi Sidana(Palo Alto University)
Cited by 13
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k